Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Sergiu Pasca, Matthew Guo, Shiyu Wang, Kristin Stokvis, Audra Shedeck, Aparna Pallavajjala, Lisa Haley, Cynthia Shams, Roshni Pallavajjala, Christopher D. Gocke, Amy E. DeZern, Ravi Varadhan, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 3429–3430.

https://doi.org/10.1182/blood-2022-169413

Published: 2022

Journal Articles

Plasma EBV DNA Methylation: Evidence of EBV Lytic Infection in HIV(+) EBV(+) Plasmablastic Lymphoma

Rena R. Xian, Jennifer Stone, Karin Miller, Lisa Haley, Prisca Mbonu, Moosa Patel, Atul Lakha, Vinitha Philip, Philippa Ashmore, Sugeshnee Pather, Wendy Susan Stevens, Christopher D. Gocke, Neil Martinson, Richard F. Ambinder, Samantha Vogt

Blood (2022) 140 (Supplement 1): 11914–11915.

https://doi.org/10.1182/blood-2022-158540

Published: 2022

Journal Articles

Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease

Sergiu Pasca, Shiyu Wang, Susan Langan, Aparna Pallavajjala, Lisa Haley, Christopher D Gocke, Wendy S Post, Matthew Budoff, Sabina Haberlen, Todd Brown, Joseph Margolick, Richard F. Ambinder, Lukasz P. Gondek

Blood (2021) 138 (Supplement 1): 4298.

https://doi.org/10.1182/blood-2021-152860

Published: 2021

Journal Articles

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

Christopher J. Gibson, MD, Haesook T. Kim, PhD, H. Moses Murdock, MD, Bryan Hambley, MD, Lin Zhao, MD, Lisa Green, PhD, Mark Fleharty, Brendan Blumenstiel, Carrie Cibulskis, BSc, Christopher D Gocke, MD, Sarah Nikiforow, MD PhD, Amy E. DeZern, MD, Vincent T. Ho, MD, Richard J. Jones, MD, Niall Lennon, PhD, Jerome Ritz, MD, Robert J. Soiffer, MD, Lukasz P. Gondek, MDPhD, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142925

Published: 2020

Journal Articles

Cancer spectrum and outcomes in the Mendelian short telomere syndromes

Kristen E. Schratz, Lisa Haley, Sonye K. Danoff, Amanda L. Blackford, Amy E. DeZern, Christopher D. Gocke, Amy S. Duffield, Mary Armanios

Blood (2020) 135 (22): 1946–1956.

https://doi.org/10.1182/blood.2019003264

Published: 2020

Includes: Supplemental data

Journal Articles

ATM Germline Variant Increases the Risk of MPN Progression

Theodoros Karantanos, MD PhD, Shruti Chaturvedi, MBBS, MS, Christopher D Gocke, MD, Donna Marie Williams, PhD, Alison R. Moliterno, MD, Evan M Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 835.

https://doi.org/10.1182/blood-2019-125362

Published: 2019

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Mark J. Levis, MD, Wenge Shi, PhD, Ken CN Chang, PhD, Christian Laing, PhD, Flora Berisha, MS, Emily Adams, BS, MB(ASCP)CM, Christopher D Gocke, MD, Wei Ding, PhD, Kenji Nakamaru, Jelveh Lameh, PhD, Reinhold Pollner, Ken Kobayashi, MD

Blood (2018) 132 (Supplement 1): 1459.

https://doi.org/10.1182/blood-2018-99-110438

Published: 2018

Journal Articles

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

Evan M Braunstein, MDPhD, Donna Marie Williams, PhD, Igor Makhlin, MD, Aparna Pallavajjala, Christopher D Gocke, MD, Nara Sobreira, MD, Kala Visvanathan, MD, Linda Resar, MD, Jerry L. Spivak, MD, Alison R. Moliterno, MD

Blood (2017) 130 (Supplement 1): 1663.

https://doi.org/10.1182/blood.V130.Suppl_1.1663.1663

Published: 2017

Journal Articles

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

Rena R. Xian, MD, Genevieve M. Crane, MD PhD, Lisa M. Haley, Christopher D. Gocke, MD, Ming-Tseh Lin, MD PhD, Aparna Pallavajjalla, Michael J. Borowitz, MD PhD, Lode J. Swinnen, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 2955.

https://doi.org/10.1182/blood.V124.21.2955.2955

Published: 2014

Journal Articles

Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.

Michael R. Grunwald, MD, Ming-Tseh Lin, MD, PhD, Keith W. Pratz, MD, Christopher D. Gocke, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 2479.

https://doi.org/10.1182/blood.V120.21.2479.2479

Published: 2012

Journal Articles

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice M. Davis-Sproul, Nilanjan Ghosh, Heather J. Symons, MD, MHS, Javier Bolaños-Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

Blood (2012) 120 (21): 3084.

https://doi.org/10.1182/blood.V120.21.3084.3084

Published: 2012

Journal Articles

Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A -158 Polymorphism Over HLA Matching.

Yvette L. Kasamon, Richard J. Jones, Christopher D. Gocke, Javier Bolaños-Meade, Lode J. Swinnen, Amanda Blackford, Douglas E. Gladstone, Ephraim J. Fuchs, Richard F. Ambinder

Blood (2012) 120 (21): 3107.

https://doi.org/10.1182/blood.V120.21.3107.3107

Published: 2012

Journal Articles

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie L. Popplewell, Thomas M. Habermann, Joseph M. Herman, William H. Matsui, Richard J. Jones, Richard F. Ambinder

Blood (2012) 119 (18): 4129–4132.

https://doi.org/10.1182/blood-2012-01-402792

Published: 2012

Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Blood (2012) 119 (1): 55–63.

https://doi.org/10.1182/blood-2011-08-370825

Published: 2012

Includes: Supplemental data

Journal Articles

Clonal immunoglobulin DNA in the plasma of patients with AIDS lymphoma

Nina D. Wagner-Johnston, Lan Gellert, Christopher D. Gocke, Victor M. Lemas, Jeannette Lee, Otoniel Martínez-Maza, Richard F. Ambinder

Blood (2011) 117 (18): 4860–4862.

https://doi.org/10.1182/blood-2010-12-324657

Published: 2011

Includes: Supplemental data

Journal Articles

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Christopher G. Kanakry, Allan D. Hess, Christopher D. Gocke, Christopher Thoburn, Ferdynand Kos, Christian Meyer, Janet Briel, Leo Luznik, B. Douglas Smith, Hyam Levitsky, Judith E. Karp

Blood (2011) 117 (2): 608–617.

https://doi.org/10.1182/blood-2010-04-277939

Published: 2011

Journal Articles

Response: Hodgkin lymphoma stem cells

Richard J. Jones, Christopher D. Gocke, Richard F. Ambinder, William Matsui

Blood (2009) 114 (18): 3971–3972.

https://doi.org/10.1182/blood-2009-08-237545

Published: 2009

Journal Articles

Circulating clonotypic B cells in classic Hodgkin lymphoma

Richard J. Jones, Christopher D. Gocke, Yvette L. Kasamon, Carole B. Miller, Brandy Perkins, James P. Barber, Milada S. Vala, Jonathan M. Gerber, Lan L. Gellert, Mark Siedner, M. Victor Lemas, Sarah Brennan, Richard F. Ambinder, William Matsui

Blood (2009) 113 (23): 5920–5926.

https://doi.org/10.1182/blood-2008-11-189688

Published: 2009

Includes: Supplemental data

NARROW

Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Plasma EBV DNA Methylation: Evidence of EBV Lytic Infection in HIV(+) EBV(+) Plasmablastic Lymphoma

Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

Cancer spectrum and outcomes in the Mendelian short telomere syndromes

ATM Germline Variant Increases the Risk of MPN Progression

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A -158 Polymorphism Over HLA Matching.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Clonal immunoglobulin DNA in the plasma of patients with AIDS lymphoma

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Response: Hodgkin lymphoma stem cells

Circulating clonotypic B cells in classic Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only